Maiva Pharma Expands Generic Sterile Injectable Manufacturing with New India Facility

Maiva Pharma Launched New State-of-the-art Sterile Injectable Manufacturing Facility in India

Six manufacturing lines were introduced to enable the production of various sterile injectable formats, including suspensions, lyophilized formulations, vials, and pre-filled syringes to cartridges. Maiva Pharma is a leading global contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO), specialising in sterile injectables.

The Facility Strengthens its Position as a Trusted Partner to Global BioPharma Companies

This facility aims to strengthen the development and manufacturing of generic and complex sterile injectable products. It was also designed to support the emerging opportunities through world-class quality systems, advanced manufacturing technologies, and flexible production capabilities.

However, this facility covers six manufacturing lines capable of producing several sterile injectable dosage forms, including cartridges, vials, pre-filled syringes, suspension products, and lyophilized formulations. It was supported by state-of-the-art microbiology laboratories and advanced quality control chemical laboratories. It enables detailed quality assurance functions and analytical testing in-house.

According to Precedence Research, the generic sterile injectable market size was calculated at USD 51.17 billion in 2025 and is predicted to increase from USD 56.41 billion in 2026 to approximately USD 124.44 billion by 2035, expanding at a CAGR of 9.29% from 2026 to 2035, due to advanced manufacturing capacity and outsourcing, technological adoption, CDMO reliance, and emerging export hubs. The streamlined regulatory frameworks, such as generic approval policies and favorable FDA policies, have accelerated increased approvals.

Industry Impact and Market Outlook

The generic sterile injectable market is dominated by global market leaders such as Pfizer Inc., Fresenius Kabi, Teva Pharmaceutical Industries Ltd., Sandoz AG, and Hikma Pharmaceuticals PLC. The leading Indian exporters and specialists are Gland Pharma Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., and Cipla Ltd. These companies are rapidly growing due to surging global demand for oncology injectables, biosimilars, and complex generics. The core product offerings include cardiovascular agents, multi-source generic anti-infectives, generic chemotherapies, emergency drugs, infusion therapies, oncology injectables, and many more. R&D investments have focused on advancements in ready-to-use formulations, patent expiries of high-value biologics, and automated aseptic manufacturing.